Autologous Retinal Patch Graft for Refractory Large Macular Holes

Incorporating a new technique into your practice.

By Noy Ashkenazy, MD, Ryan Zukerman, BS, Ninel Z. Gregori, MD

The Retinal Drug-Delivery Pipeline

An expert roundtable discusses what's on the way for retina therapy.

By Robert L. Avery, MD, Pravin U. Dugel, MD, Allen C. Ho, MD, et al.

Sustained-Release Sunitinib Malate for Neovascular AMD

This durable agent has the potential to reduce treatment burden.

By Aamir A. Aziz, BS, Majid Khan, BS, Noah Shafi, BS, et al.

Port Delivery of Ranibizumab

Six-month or longer dosing could change the game for retina specialists.

By Nancy M. Holekamp, MD

An Antibody Biopolymer Conjugate for Enhanced Durability in Retinal Disease

The clinical development of KSI-301 is advancing rapidly.

By Carl D. Regillo, MD, FACS

Burnout in the Retina Community

Be proactive to maintain career satisfaction.

By Adam Burton, BS, Julia Hudson, MD, Jayanth Sridhar, MD

Retina Risk Management

Preparation prevents errors.

By Jeremiah Brown Jr., MS, MD , Anne M. Menke, RN, PhD, Linda Harrison, PhD, et al.

SUBSPECIALTY NEWS: Port drug delivery in DME, integrin inhibitors, treatment for XLRP, eye drops for DME, gene therapy, and more.

By Jerry Helzner, contributing editor

UPFRONT: Toward Streamlining Retina Practice

By Peter K. Kaiser, MD

CLINICAL TRIAL DOWNLOAD: Phase 1/2a Data on Human Retinal Progenitor Cell Therapy

A potential therapy for a broad patient population.

By Pravin U. Dugel, MD

CODING Q&A: Billing New Patient Exams

Avoid any missteps when coding low-risk patient exams.

By Suzanne L. Corcoran, COE

NEW PRODUCT APPLICATIONS: Upgraded Vitrectomy System Offers Surgeon-Driven Innovation

DORC's EVA now has an ergonomic foot switch and an LED light.

By Karen Appold, contributing writer

CLINICAL TRIAL UPDATE

DARPin Molecules: Faculty

An Emerging Investigational Class of Binding Protein

DARPin Molecules: An Emerging Investigational Class of Binding Protein

Artificial Intelligence for Retinal Disease

Embracing the current state of artificial intelligence and keeping our eyes on the future.

By Michael B. Rivers, MD